Evidence map›Paper›PMID 39120945›Full record

ArticleThe international journal of neuropsychopharmacology2024

Brain mGlu5 Is Linked to Cognition and Cigarette Smoking but Does Not Differ From Control in Early Abstinence From Chronic Methamphetamine Use.

Megan N McClintick, Robert M Kessler, Mark A Mandelkern, Tarannom Mahmoudie, Daicia C Allen, Hilary Lachoff, Jean-Baptiste F Pochon, Dara G Ghahremani, Judah B Farahi, Edwin Partiai and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Megan N McClintickVeterans Administration of Greater Los Angeles System, Los Angeles, California, USA.ORCID 0000-0003-3399-733X
Robert M KesslerSemel Institute and Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, California, USA.
Mark A MandelkernVeterans Administration of Greater Los Angeles System, Los Angeles, California, USA.
Tarannom MahmoudieSemel Institute and Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, California, USA.
Daicia C Allen
Hilary LachoffVeterans Administration of Greater Los Angeles System, Los Angeles, California, USA.
Jean-Baptiste F PochonSemel Institute and Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, California, USA.
Dara G GhahremaniSemel Institute and Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, California, USA.
Judah B FarahiVeterans Administration of Greater Los Angeles System, Los Angeles, California, USA.
Edwin PartiaiVeterans Administration of Greater Los Angeles System, Los Angeles, California, USA.
Robert A CasillasVeterans Administration of Greater Los Angeles System, Los Angeles, California, USA.
Larissa J MooneyVeterans Administration of Greater Los Angeles System, Los Angeles, California, USA.
Andy C DeanSemel Institute and Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, California, USA.
Edythe D LondonVeterans Administration of Greater Los Angeles System, Los Angeles, California, USA.

Funding

Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural FunctionR01DA045162 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK, MOONEY, LARISSA JEANETTE · 2018 to 2022
$3.3M
[18F] FPEB Studies of the mGluR5 Receptor and Methamphetamine AbuseR33DA031441 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KESSLER, ROBERT MICHAEL · 2017 to 2019
$1.4M
Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine UsersR21DA042347 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK · 2017 to 2018
$528k
Varenicline-associated alterations in dopamine D2-type receptors, self-control, and decision making in methamphetamine usersF32DA047111 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCCLINTICK, MEGAN N · 2018 to 2019
$120k
NIDA NIH HHS F32 DA047111NIDA NIH HHS R01 DA045162NIDA NIH HHS R21 DA042347NIDA NIH HHS R33 DA031441
6 · The paper itself

Abstract

backgroundThe group-I metabotropic glutamate receptor subtype 5 (mGlu5) has been implicated in methamphetamine exposure in animals and in human cognition. Because people with methamphetamine use disorder (MUD) exhibit cognitive deficits, we evaluated mGlu5 in people with MUD and controls and tested its association with cognitive performance.

methodsPositron emission tomography was performed to measure the total VT of [18F]FPEB, a radiotracer for mGlu5, in brains of participants with MUD (abstinent from methamphetamine for at least 2 weeks, N = 14) and a control group (N = 14). Drug use history questionnaires and tests of verbal learning, spatial working memory, and executive function were administered. Associations of VT with methamphetamine use, tobacco use, and cognitive performance were tested.

resultsMUD participants did not differ from controls in global or regional VT, and measures of methamphetamine use were not correlated with VT. VT was significantly higher globally in nonsmoking vs smoking participants (main effect, P = .0041). MUD participants showed nonsignificant weakness on the Rey Auditory Verbal Learning Task and the Stroop test vs controls (P = .08 and P = .13, respectively) with moderate to large effect sizes, and significantly underperformed controls on the Spatial Capacity Delayed Response Test (P = .015). Across groups, Rey Auditory Verbal Learning Task performance correlated with VT in the dorsolateral prefrontal cortex and superior frontal gyrus.

conclusionAbstinent MUD patients show no evidence of mGlu5 downregulation in brain, but association of VT in dorsolateral prefrontal cortex with verbal learning suggests that medications that target mGlu5 may improve cognitive performance.

Indexed as

Amphetamine-Related DisordersBrainCigarette SmokingMethamphetaminePositron-Emission TomographyReceptor, Metabotropic Glutamate 5AdultCentral Nervous System StimulantsCognitionExecutive FunctionFemaleHumansMaleNeuropsychological TestsCentral Nervous System StimulantsGRM5 protein, humanMethamphetamineReceptor, Metabotropic Glutamate 5dorsolateral prefrontal cortexGroup-I metabotropic glutamate receptor subtype 5positron emission tomographystimulant use disorderverbal learning

Identifiers

PMID39120945
PMCPMC11348008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.